Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) ...

Signing of a Patent License Agreement with Tufts Medical Center to jointly advance the development of tafenoquine for babesiosis treatment, indicating a strategic collaboration that enhances the ...

WASHINGTON, July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (SXTP) (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on ...

OFFICERS TRUE HEROES. MULTIPLE CONFIRMED CASES. AND I’M GOING TO LET THE DOCTOR HERE TAKE THIS WORD. BABESIOSIS IN MASSACHUSETTS, THAT’S A DISEASE PRIMARILY SPREAD BY DEER TICKS. SO WE TALK A LOT ...

60 Degrees Pharmaceuticals, Inc. announced the enrollment of the first patient in an expanded access study (NCT06478641) assessing the effectiveness of tafenoquine in treating patients with persistent ...

Tick-borne diseases are spreading into new parts of the United States at a pace that has caught public health officials off guard. Babesiosis, a potentially fatal parasitic infection once confined to ...

Cases of a tick-borne parasitic disease have steadily increased in recent years, a new study shows. Rates of babesiosis increased an average 9% a year in the United States between 2015 and 2022, ...

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning ...

Add Yahoo as a preferred source to see more of our stories on Google. https://www.tipranks.com/news/the-fly/wells-sees-potential-upside-after-glaukos-idose-repeat ...

A pilot study has found evidence of Bartonella and Babesia infection in almost half of 50 blood samples from patients suffering chronic fatigue syndrome, also called myalgic encephalomyelitis (ME).